Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Amarin Corporation plc

< Previous 1 2 3 Next >
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Chairman & CEO Issue Letter to Shareholders
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Reports Third Quarter 2023 Financial Results
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Latest Research Evaluating VASCEPA®/VAZKEPA® (icosapent ethyl) and Subgroups from the REDUCE-IT Landmark Outcomes Trial to be Presented at the American Heart Association (AHA) Scientific Sessions 2023
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin to Report Third Quarter 2023 Financial Results and Host Conference Call on November 1, 2023
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin to Present at the 2023 Cantor Global Healthcare Conference
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Provides Pricing & Reimbursement Updates for VAZKEPA (icosapent ethyl) in The Netherlands and Italy
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in Israel
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Scottish Medicines Consortium Accepts VAZKEPA® (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland(1)
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Reports Second Quarter 2023 Financial Results
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Receives Positive Recommendation from Spanish Drug Pricing Committee for National Reimbursement of VAZKEPA® (icosapent ethyl) in Spain
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Board of Directors Announces Executive Compensation Program for New President and CEO Patrick Holt
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Appoints Patrick Holt as President and Chief Executive Officer
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Implements Organizational Restructuring to Strengthen the Company While Driving Patient Access to VASCEPA®/VAZKEPA® Globally
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Announces Vascepa® (Icosapent Ethyl) Approved to Reduce Cardiovascular Risk in the Kingdom of Saudi Arabia (KSA)
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin to Present at Two Upcoming Investor Conferences
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Partner EddingPharm Receives Regulatory Approval for Vascepa® (Icosapent Ethyl) in Mainland China
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Reports First Quarter 2023 Financial Results and Provides Business Update
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS